Transformative Imaging for Quantitative Biology (TIQBio) Partnership

定量生物学的变革成像（TIQBio）合作伙伴关系旨在为英国Plc的利益开发颠覆性技术，并解决工业和学术界的问题。目前用于观察临床前生物样本的主要成像方法是荧光显微镜。这项技术依赖于标签的使用，当被显微镜照射时，标签会发光，从而确定它们所附着的结构或分子的位置。对任何生命系统来说，标签的插入或附着都是一种侵入性过程，可以改变其行为和运作方式。此外，所有的生命系统、组织和细胞本质上都是三维的。因此，在三维图像中，必须逐点采集荧光信号并重建图像。这是一个非常缓慢和破坏性的过程，特别是对于代表现实生活条件的3-D活体样本。为了发现新药或研究疾病或治疗的机制，很明显，在进行人体试验之前，应该使用尽可能接近现实生活的条件。这就是为什么大多数生物医学研究人员和在疾病、药物或治疗领域工作的工业部门希望使用类生命样本的原因。然而，目前还不存在以不受干扰、无损伤的方式对它们进行3D成像的工具。此外，在最高分辨率下工作是可取的，这样我们就可以看到纳米级生物系统中存在的最小的东西，并获得有关化学成分和结构顺序的整体信息。这些信息将揭示前所未有的洞察力，从而有助于了解疾病，或为什么特定的候选药物起作用或不起作用，从而制造更好的药物。TIQBio将解决这些挑战，以便以前所未有的全3D分辨率水平进行不受干扰的实时成像，并在100个测试生物模型上快速执行多个读数的整体信息。这些创新的工具和技术将使药物的发现得到改进，降低将药物推向市场的成本，使制药业和患者都受益。由于拟议的颠覆性技术，罕见病患者或低收入国家的患者可能获得新药。生物医学研究人员将从中受益，因为他们将能够理解现象，而不会因为标签而产生误导性的结果；使用逼真的模型将通过开发治疗方法或防御对策，更好地告知或保护公众。

The Transformative Imaging for Quantitative Biology (TIQBio) partnership aims to develop disruptive technology for the benefit of UK Plc and for solving problems in industry and academia. The mainstay of current imaging methods to look at pre-clinical biological samples is fluorescence microscopy. This technique relies on the use of tags, which emit light when illuminated by the microscope, allowing the location of the structures or molecules to which they are attached to be determined. Insertion or attachment of a tag is an invasive process for any living system and can alter its behaviour and the way it functions. Furthermore, all living systems, tissue and cells are inherently 3-dimensional. Therefore to image in 3D one has to point-by-point collect fluorescence signal and reconstruct an image. This is a very slow and damaging process especially for 3-D live samples that represent real-life conditions. For discovering new drugs or for studying mechanisms in diseases or healing it is obvious that one should use conditions that are as near to real life as possible, before human testing. This is why most biomedical researchers and industrial sectors that operate in the area of diseases, drugs or therapeutics want to use life-like samples. At the moment however, the tools to image them in 3D and in an unperturbed, non-damaging manner simply do not exist. Furthermore, it is desirable to work at the highest resolution so we can see the smallest things that exist at the nanoscale in such biological systems and obtain holistic information about the chemical composition and structural order. This information will reveal unprecedented insight and hence help understand diseases or why a particular drug candidate does or does not work allowing better ones to be made. TIQBio will address these challenges so that unperturbed, live imaging can be carried out at an unprecedented resolution level in full 3D, with holistic information from multiple readouts carried out rapidly on 100s of test biological models. These innovative tools and technologies will allow the discovery of drugs to be improved, reduce costs for bringing a drug to market benefiting the pharma industry and patients alike. Patients with rare diseases or in lower income countries may gain access to new drugs because of the proposed disruptive technology. Biomedical researchers will benefit as they will be able to understand phenomena without misleading results due to tags; the use of real life-like models will better inform or protect the public through the development of therapies or defence countermeasures.